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Muteins, i. e. proteins altered by mutation of their genes, of interleukin 2 (112) were generated by 
oligonucleotide-directed mutagenesis in vitro. All acidic and basic residues conserved between man and mouse 
were exchanged as weil as four lipophilic residues contained within four hydrophobic segments of the protein. 
The muteins were produced in Escherichia co/i and submitted to a renaturation and purification protocol, before 
bioactivity and receptor binding of each of them was determined. 
All muteins besides two (K44/T125 and Q110/T125) could be renatured and purified. One mutein (K94/T125) 
exhibited a more than tenfold-improved renaturation yield. 
One amino exchange (Asp-20 to Asn) resulted in an about 20-fold reduction in proliferative activity and high-
affinity receptor binding. The binding to the low-affinity Il2-binding protein (Tac antigen) was unimpaired. 
A second exchange (Arg-38 to Gin) had no effect on proliferative activity. The binding to both the high- and 
the low-affinity receptor, however, was reduced about 20-fold. 
Preliminary trials on the stability of thesemuteins by guanidinium hydrochloride denaturation studies detected 
no differences between wild-type interleukin 2 and muteins. 
It is suggested that Asp-20 forms part of the binding site for the large receptor subunit whereas Arg-38 is 
involved in the contact site to the small subunit. 
The transient synthesis of interleukin 2 (Il2) and its recep-
tor by activated T lymphocytes apparently represents an es-
sential step in the elaboration of the cellular immune response 
(for recent reviews see [1- 3]). The binding of 112 to a high-
affinity receptor (Kd ~ 10 pM) provides the growth-signal 
leading to the clonal expansion of antigen-specific T cells. 
Interestingly, the high-affinity receptor has been estab-
lished to be assembled from a low-affinity (Kd ~ 10 nM) ll2-
binding protein of Mr 55000 (Tac antigen, ß subunit) and an 
intermediate-affinity ( Kd ~ 1 nM) receptor protein of Mr 
70000-75000 (a subunit) that is likely to represent the 
growth-signal-transducing moiety [4, 5]. The human Il2 se-
creted by activated T cells is a 133-residue glycoprotein [6, 7]. 
The cDNA has been cloned [8, 9] and could be efficiently 
expressed in Escherichia coli. The recombinant Il2 when prop-
erly renatured and purified exhibits a specific biological ac-
tivity as high as the authentic T cell product. The availability 
of chemical ·quantities of recombinant 112 paved the way for 
studies on its potential use as immunotherapeutic agent (see 
e.g. [10]) and for studies on its biochemical properties. The 
three-dimensional structure at 0.3-nm resolution has been 
described recently [11). 
Several previous communications have addressed the 
question of receptor-binding site(s) on the Il2 protein by using 
immunological [12-14) or genetic techniques [15-18]. The 
analyses of mutant proteins (muteins) of Il2 remairred to a 
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large extent preliminary, however, since the proteins were 
not renatured and purified before measuring proliferative or 
receptor-binding activity. Thus, effects of a certain mutation 
on the folding or on the receptor-binding sites could not be 
clearly differentiated. 
During the studies presented in this paper a series of 
charged residue positions and of hydrophobic positions were 
exchanged which cover more or less the whole surface of 
112. The muteins were all submitted to a renaturation and 
purification protocol before analysing biological activities. 
Two muteins appeared which define positions involved in 
high- or in Iow-affinity receptor binding. Surprisingly, one 
mutein was obtained exhibiting a large increase in yield during 
renaturation. 
METHODS 
Construction ofmutant strains 
A cDNA coding for the mature part of human 112 [8] plus 
an initiator methionine [19] was submitted to oligonucleotide-
directed mutagenesis by the gapped duplex DNA approach 
[20, 21J. The synthetic oligonucleotides comprised 6-16 resi-
dues before and after the nucleotide(s) to be exchanged, and 
they were provided by Dr H. Blöcker (GBF. Braunschweig) 
or synthesised on a DNA synthesiser (Applied Biosystems, 
model 380). Mutations in the Thr-125 background were con-
structed by starting with a cDNA containing an ACT codon 
in place ofthe TOT coding for Cys-125 ofwild-type 112. Each 
mutation was detected by DNA sequence analysis of single-
stranded bacteriophage DNA. 
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The mutated cDNA was excised as an Neo!- BamHI 
fragment from the double-stranded viral DNA and recom-
bined with a temperature-regulated expression vector 
pRT8pRC109 which is similar to PILA 502 [22] with the excep-
tion that the Iambda leftward promotor and the polylinker 
are missing. A recA- derivative of E. coli strain JM103 [23] 
was used as host. The integrated Il2 cDNA was sequenced 
and, when the mutation had been confirmed, the strain was 
used for the expression of the mutein. 
Isolation of 112 muteins 
An E. coli strain exhibiting temperature-regulated ex-
pression of a mutein was grown at 30 oc in 0.8 I Luria broth 
plus ampicillin (50 J.tg/ml) to an A 550 of 0.5. The 2-l flasks 
were then immediately transferred to a rotatory water bath 
and incubated at 42 "C for another 2-3 h at 200 rotations/ 
min to an A550 of 1.2-1.5. The cells (1.5- 2 g wet mass) were 
harvested by centrifugation for 10 min at 6000 x g, washed 
once with 50 mM TrisjHCl, pH 8, and frozen at -20°C. 
The recombinant Il2 muteins were renatured and purified 
according to Kato et al. [24] with some modifications. Briefly, 
cells dispersed in 10 vol. (vol.jwet mass) sucrose/Tris/EDTA 
buffer (0.375 M sucrose, 10 mM Tris/HCl pH 8, 1 mM 
EDTA) were sonicated five times for 1 min at 300 W in an ice 
bath. The particulate fraction containing inclusion bodies of 
the highly expressed mutein was sedimented at 17 000 x g for 
20 min at 4 °C. The supernatant and a greenish fluffiy layer 
were discarded. The tight white sedimentwas washed by resus-
pension and centrifugation once with sucrosejTris/EDTA 
buffer and twice with Tris/EDTA buffer (50 mM Tris/HCl 
pH 8, 1 mM EDTA). The final sediment (0.3- 0.4 g wet mass) 
was suspended in 10 vol. 0.1 M TrisjHCl, pH 8, yielding 
about 20 mg protein/ml. 
The protein was dissolved by adding 3 vol. 8 M guani-
dinium chloride in 0.1 M Tris/HCI, pH 8, and 0.1% (by vol.) 
2-mercaptoethanol. After incubation for 2 h at ambient tem-
perature, the mixturewas clarified by a 15-min centrifugation 
at 17000 >< g also at ambient temperature. The resultant solu-
tion, containing about 5 mg protein/ml, was diluted fivefold 
with ice-cold water, and was then dialysed for 16- 20 h at 
4°C against 20 vol. 10 mM Tris/HCl, pH 8, 1 mM EDTA. 
The very doudy suspensionwas adjusted to pH 5 with acetic 
acid and centrifuged for 20 min at 17 000 x g. 
The supernatant was pumped over 2 ml CM-Sepharose 
CL-6B (Pharmacia) equilibrated with 25 mM ammonium 
acetate, pH 5. The adsorbed I12 was eluted with a linear 
gradient of 0-0.5 M NaCl in 25 mM amrnonium acetate, 
pH 5. 
The eluted Il2-containing fractions were pooled and sub-
mitted directly to HPLC over a C4 column (Vydac 214 TP54). 
The column was developed with a gradient of 28-70% 
acetonitrile in 0.1 % trifluoroacetic acid in water. The eluted 
protein was pooled and stored as aliquots at -20 oc. 
Preparations of 3 H-labeled 112 
Mutein T125 was mass-labeled with 3 H-labeled amino 
acids (TRK 550, Amersham) and isolated as described above 
with the foiJowing modifications. Cells were grown in 10 ml 
Vogel Bonner minimal medium plus 50 Jlg ampicillin/ml. 3H-
labeled amino acids were added (2.5 mCi in 250 Jll water) 
3 min after transfer ofthe culture to 42°C. Cells were harvest-
ed 30-60 min later. Inclusion bodies were dissolved in 500 Jll 
6 M guanidinium hydrochloride. Omitting the CM-Sepharose 
chromatography, the supernatant after dialysis was mixed 
with an equal volume of 0.1% trifluoroacetic acid, centri-
fuged, and the supernatant was then submitted immediately 
to HPLC. The amount of Il2 (0.9- 6 ~-tg) was estimated by 
a pro1iferation assay and detennined by competition with 
unlabeled 112 in a receptor-binding assay. Specific radioactivi-
ties obtained ranged over 100-360 nCijpmol Il2 (6.7-
24 J,tCi/J.tg Il2). 
Proliferation assays 
The bioactivity of Il2 and 112 muteins was estimated by 
measuring eH]thymidine incorporation into an 112-dependent 
murine T cell line [25] (CTLL-2; ATCC MB214) or con-
canavalin-A-activated human peripheral blood cells [26] 
(Blutbank des Deutschen Roten Kreuzes, Würzburg). The 
assays were calibrated with the !12 standard from the Biologi-
cal Response Moditier Program (NIH, Bethesda). 1 unit Il2/ 
ml gave a half-maximal response in the murine CTLL assay. 
Receptor binding 
For high-affinity binding 2 >< 106 HUT 102 (ATCC 
TIB162) cells were incubated for 1 hat 4 oc with 250 pM 3H-
labeled Il2 (mutein T125) plus serial dilutions of unlabeled 
muteins from 0.05 pM to 50 nM. Bound radioactivity was 
measured after washing twice with ice-cold incubation me-
dium (RPMI plus 10% fetal calf serum) by resuspension and 
centrifugation for 10 s at 7000 >< g. 
For low-affinity binding [27], 106 HUT 102 cells were 
incubated for 1 h at 4 oc with 10 nM 3H-labeled 112 ( mutein 
T125) plus serial dilutions of unlabeled muteins from 1 nM 
to 5 J.tM. Cells were immediately centrifuged through a silicon 
layer for determination of bound Il2. Sedimented cells were 
suspended in 0.1 ml incubation buffer, mixed with 0.1 ml2% 
SDS in the scintillation vial before addition of 3 ml emulsifier 
Scintillator 299™ (Packard). 
Guanidinium hydrochloride denaturation curves 
HPLC~purified Il2 muteins were lyophylised and dissolved 
at a concentration of 10 J.tM ( = 150 J.tg/ml) in 25 mM am-
monium acetate, pH 5. The protein was then diluted to 1 ~-tM 
to achieve the different guanidinium chloride concentrations 
(0-7.2 M) in the pH-5 buffer. Fluorescence emission spectra 
were recorded between 300-450 nm during excitation at 
290 nm (fluorescence spectrophotometer, Schoeffel model 
RRS 1000). 
Analytical procedures 
Protein was determined in the inclusion bodies by the 
Lowry method [28] after precipitation with trichloroacetic 
acid in the presence of deoxycholate. Protein of purified 112 
muteins was measured by absorbance at 280 nm using an 
absorption coefficient of 1.22 x 104 M- 1 cm - 1 (1 mg Il2/ml 
yields an absorbance at 280 nm of 0.8). Proteins dissolved in 
dodecyl sulfate were separated by electrophoresis on 12% 
polyacrylamide gels according to [29]. 
RESULTS 
Purification and renaturation of recombinant Il2 muteins 
The human recombinant Il2 after heat induction consti-
tuted 25- 30% of the total E. coli protein. lt was quantita-
a b e d e 
--112~ 
Fig. 1. Purification of recombinant human 112 from E. coli. The various 
protein fractions were submitted to SOS gel electrophoresis and 
stained with Coomassie blue. Lanes show protein (a) of whole cells, 
(b) of supernatant, (c) of particulate fraction ( = inclusion bodics), 
(d) after CM-Sepharose chromatography, and (e) after HPLC 
tively recovered in the particulate fraction of the broken cells 
(inclusion bodies) contaminated to less than 10% by other 
proteins. The protein was dissolved completely in 6 M 
guanidinium chloride. After the renaturation step, however, 
only a small percentage was recovered in soluble form. Minor 
amounts of contaminating proteins and other ultraviolet-ab-
sorbing substances were removed and the renatured 112 was 
concentrated by CM-Sepharose ·chromatography at pH 5. 
The final purification was achieved by HPLC. The gel 
electrophoretic analyses of the various fractions obtained dur-
ing a representative purification are shown in Fig. 1. 
In Table 1 the amino acid exchanges of the constructed 
and analysed muteins are compiled, tagether with the location 
in helices A- F or in helix-connecting loops according to the 
three-dimensional structure [11]. Most of thesemuteins could 
be renatured and purified in yields comparable to the wild 
type, i.e. from 100 mg protein ofinclusion bodies 0.8-2.4 mg 
protein ofthe finally purified muteins were obtained (Table 2). 
I t has not been analysed whether this range of differences in 
yield was caused by specific properlies of certain muteins or 
by experimentation. 
For some muteins, however, much more pronounced devi-
ations in renaturation yield were observed. The Phe-44 to 
Lys or the Glu-110 to Gin exchange completely prevented 
renaturation und er the conditions applied. On the other band, 
the K94/T125 mutein was recovered with a final yield ofabout 
25% based on the protein content of the inclusion bodies 
(Table 2). It is worth noting that, ifthe guanidinium-chloride-
dissolved muteins were submitted to a proliferation assay, 
extremely low specific activities were observed for the two 
non-renaturing muteins ( < 103 U jmg) whereas a maximal 
specific activity of 2-4 x 107 Ujmg proteinwas observed for 
the super-renaturing K94/T125 mutein. 
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Table 1. Muteins o.f human inter Ieukin 2 
For designation of the muteins, thc amino acid in the one-letter 
code designates the new residue(s) introduced at each position. The 
numbering is according to [Ala]interleukin 2 [8, 9]. The segments, i. c. 
helices and helix-connecting loops, are taken from [11]. The second 
exchange at T125 is not considered 
Mutein Affected segment 
Wild type 
8125 F 
A125 F 
T125 F 
Q15 A 
Q15/T125 
N20 AB 
N20/T125 
Q32 AB 
Q32/T125 
Q35 B 
Q35/T125 
Q38 B 
Q43 B 
Q43/T125 
Q48/T125 B' 
Q49/T125 B' 
Q52 B' 
Q54/T125 B' 
Q60/T125 B'C 
Q61/T125 B'C 
Q62/T125 B'C 
Q76/T125 c 
N84/T125 D 
Q97 0 
Q100/T125 D 
Q110/T125 E 
Q116 EF 
Q120/T125 F 
K19/T125 AB 
K25/T125 AB 
K44/T125 B 
K94/T125 D 
Table 2. Yield of interleukin 2 and muteins during purification 
The muteins are described in Table 1 
Fraction 
Inclusion bodies 
After CM·Sepharose 
After HPLC 
Yield of 112 and muteins 
K44/T125; 
Q110/T125 
%total 
= 100 
< 0.1 
< 0.1 
K94/T125 
= 100 
27-40 
22-38 
all others 
= 100 
1.9-4.6 
0.8-2.4 
The removal of Cys-125 does not influence renaturation 
yields to a major extent. The S125, A125 and T125 muteins 
are recovered during the present protocol in the 0.8-2.5% 
range observed with most of the other muteins. Some ex-
changes have been constructed in the Thr-125 background 
as well as in the Cys-125 background; similar results· were 
obtained. 
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Fig. 2. Prol!ferative activity and high-alfinity receptor binding of re-
natured and purified 112 muteins. 112 wild type and the muteins Jisted 
in Table 1 were analysed in a proliferation assay with murine CTLL2 
cells (A) and human concanavalin-A-stimulated blast cells (B). The 
mean value of the specific activities of the wild-type-like muteins was 
taken as 100% (3 x 107 U/mg protein for CTLL2 cells and ConA 
blasts). (C) The concentration of a mutein causing half-maximal rc-
duction of 3H-labcled mulein T125 binding (IC50) was related to the 
IC50 of mutein Tt25. The ratio ( x 100) of IC50 for T125/IC 5o for 
mutein is plotted 
Proliferative activity of Il2 muteins 
with murine and human T cells 
The renatured and thoroughly purified muteins were ana-
lysed for their biological activity in a proliferation assay with 
murine CTLL cells and with human concanavalin-A-activated 
T lymphocytes. The resulting specific activities were related 
to the mean value of all measurements which was set as 100% 
(Fig. 2). The specific activity of wild-type 112 varied between 
2-4 x 107 U/mg protein during these measurements. 
Most muteins exhibited specific activities similar to that 
of the wild type and with a variability among the muteins 
similar to the variability among multiple measurements ofthe 
same mutein. Two notable exceptions occurred, however. The 
muteins N20 and N20/T125 both showed specific activities 
significantly lower than that ofthe other proteins. This applied 
for the assay with both the murine and human T cells. Since 
the Thr-125 exchange alone had no effect, the exchange of 
Asp-20 to Asn was identified independently in the two muteins 
to ca use an about 10-20-fold reduced biological activity. 
Binding of the ll2 muteins to the human high-a[finity receptor 
The binding of the muteins to the high-affinity receptor 
present on HUT 102 cells was estimated in competition exper-
~ 
6 
.... 
Q 
~ 100 
w-8 10"' to-6 w·S 
Mutein IMJ 
Fig. 3. Competition of I/2 and muteins for the low-affinity receptor. 
HUT 102 cells were incubated with mixtures of 3H-labeled mutein 
T125 (1 0 nM) and the concentrations of the unlabeled muteins indi-
cated in the abscissa. Bound 3H-labeled mutein Tt25 was determined 
after competition with unlabeled muteins T125 ( e ), N20 ( 0 ), and 
Q38 ( x) 
iments employing mass-3H-labeled mutein T125. The 3 H-
labeled 112 was present in the binding assay at 250-500 pM. 
This concentration is between the dissociation constants of 
the high- and the low-affinity receptor, which were about 
50 pM and 20 nM, respectively, in the experiments described. 
The concentration of a mutein necessary for half-maximal 
competition of the 3H-labeled mutein T125 was determined. 
The binding potencies, i.e. the ratio of IC 50 for Il2 to IC50 
for mutein is compiled for allmuteins in Fig.2C. 
The receptor binding was similar to the wild type for 
most of the muteins. However, muteins N20 and N20/T125 
had a 10-20-fold lower potency, in line with results of the 
proliferation assays. 
Surprisingly, the mutein Q38 also had a much reduced 
potency as confinned with different preparations. This result 
is puzzling, since mutein Q38 exhibited completely normal 
specific activities during the proliferation assays. 
For some muteins, i.e. K19/T125, K25/T125 and Q16, 
slightly reduced or increased potencies in receptor binding 
were measured. These proteins were not further analysed in 
the present study. 
Binding ofmuteins N20 and Q38 to the low-ajfinity receptor 
The altered binding affinities of muteins N20, N20/T125, 
and Q38 to the high-affinity receptor Ieads to several ques-
tions. First of all, is it possible to observe similar alterations 
in the binding to the low-affinity receptor? 
The results of a competition of these muteins for the bind-
ing of 10 nM 3H-labeled muteins T125 to HUT 102 cells are 
shown in Fig. 3. Both the mutein N20 and N20/T125 com-
peted for the Iow·affinity receptor at the same concentrations 
as the wild-type-like mutein T125. In contrast, mutein Q38 
had a 10- 20-fold lower potency. 
Stability ofmuteins in guanidinium ch/oride 
The altered functional properties of the above-mentioned 
muteins might be caused by conformational features of these 
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Fig. 4. Guanidinium hydrochloride denaturation curves for selected 112 muteins. Fluorescence emission spectra were recorded for the individual 
proteins dissolved at the indicated concentrations of guanidinium hydrochloride, as shown in (A) for mutein Q38 dissolved at 1 ~J.g/ml in 
25 mM ammonium acetate pH 5 (--- -) or in the same buffer plus 7.2 M guanidinium chloride (--) (B). The fluorescence intensities at 
360 nm were plotted for muteins Tt 25 ( e ), N20 ( 0 ), and Q38 ( x) 
proteins, despite their normal behaviour during renaturation 
and isolation. Therefore, their stability in a chaotropic agent 
was analysed [30]. 
The single Trp-121 of human 112 exhibits a fluorescence 
emission spectrum with a maximum at 335 nm. According to 
fluorescence quenching experiments this Trp is buried [31, 32]. 
During denaturation in concentrated guanidinium chloride 
solution the maximumwas shifted rapidly, i.e. faster than in 
1 s, to 360 nm and the intensity at this wavelength increased 
about fivefold (Fig. 4A). A reverse rapid shift was observed 
when the denaturing solution was diluted. 
The emission spectra were recorded for muteins N20, Q38 
and for the wild-type-like mutein T125 at increasing concen-
trations of guanidinium chloride. As shown in Fig.4B, the 
dose/response curves for the three proteins anaJysed are very 
similar at concentrations of guanidinium chloride higher than 
2M. The half-maximal effect is observed at 4 M guanidinium 
chloride. Thus, the stability of 112 is not affected in the muteins 
under the conditions applied at least as far the environment 
ofTrp-121 is concerned. 
At lower concentrations of guanidinium chloridevariable 
intensities at 360 nm were observed. This appears to reflect a 
variable degree of denaturation of the different proteins dur-
ing the lyophilisation from 0.1% trifluoroacetic acid in 60% 
acetonitrile (see Methods). 
DISCUSSION 
The aim of the present study was to identify surface resi-
dues in human Il2 that provide part ofthe binding site for the 
receptor. The experimental approach was to modify amino 
acid residues by site-directed mutagenesis, to produce the 
resultant muteins in E. coli, and to analyse them for their 
biological activity. This approach has several intrinsic prob-
lems, some of which are difficult to overcome. First of all, 
structural effects of an amino acid exchange should be sepa~ 
rated as far as possible from functional effects. In previous 
communications on human and murine Il2 muteins, the func-
tional activity of muteins was tested on the Ievel of detergent-
solubilised E. coli cells or inclusion bodies [16, 18]. While it 
is quite clear that these protein fractions contain initially a 
denatured and reduced !12, it is completely uncertain how far 
the protein renatures during dilution or during the assays. 
Thus, the activities reported might represent a residual activity 
of an unfolded or partially refolded protein or the full activity 
of a small percentage of fully renatured protein. A reduced 
activity of a mutein may be caused by a defect in refolding or 
a defect in receptor binding. Actually it would be interesting 
to know whether the completely unfolded 112 has residual 
receptor binding activity (see [17]). 
In the present study, muteins which survived the applied 
renaturation and purification procedure were considered to 
be renatured, i. e. functionally refolded. This operational defi-
nition of renaturation appears to be justified since wild-type 
112 and most ofthe muteins are recovered with normal biologi--
cal activity. A final proof for a renaturation has to await 
crystallisation and X-ray analysis of a mutein. 
Nevertheless, several interesting results were obtained on 
the present Ievel of sophistication. The lack of renaturation 
after modification of positions 44 (hydrophobic) and 110 
(polar) is most easily explained if the affected side chains are 
normally buried within the protein and thus contribute to the 
stabilisation of the tertiary structure. Otherwise, Il2 aggre-
gates at neutral pH already at a low concentration (Kd of 
0.6 J..LM) [31]. Possibly, in the two nonrenaturing muteins the 
aggregation tendency of a refolding intermediate is enhanced. 
Modification of juxtaposed positions Lys-43 to Gln and Asp-
109 to Asn [33] have no detectable effects. Unfortunately, at 
this time the three-dimensional structure of human Il2 has 
been resolved to 0.3 nm only [11]. This low resolution does 
not distinguish whether the substituted residues are located 
at the surface or the interior of the protein. 
The overall yield of renatured and purified Il2 generally 
was low (0.8- 2.4% ). The finding that the modification of 
hydrophobic position Leu-94 to Lys enhances the yield more 
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than tenfold came as a surprise. This effect cannot yet be 
explained. The solubility of the mutein at neutral pH value 
appears not to be altered to a major extent. 
The proliferation assay yielded specific activities for all 
muteins as high as the wild type, within the accuracy of the 
determination, with one exception: the alteration ofthe acidic 
position Asp-20 to Asn reduced activity more than tenfold. 
The same position had been substituted isofunctionally (Asp 
to Glu) previously without effect on the activity of the de-
natured protein [16]. The drastic modification of the juxta-
posed hydrophobic position Leu-19 to Lys had no major 
effect. A fine structural deletion analysis with mouse ll2 estab-
lished that a segment corresponding to human 112 position 
18-21 cannot be deleted without interfering with the struc-
ture or function of the protein [18]. This segment represents 
the last turn of helix A and the first residue of the long loop 
connecting helices A and B [11 ]. 
A reduced activity of a mutein in the proliferation assay 
can have different causes, e. g. reduced stability, reduced affin-
ity for the receptor, or an increased turnoverjdegradation of 
the mutein-receptor complex in the cell. Actually, the prolifer-
ation activity and binding affinity for the high-affinity recep-
tor decreased in parallel for the two N20 muteins analysed. 
For all other muteins both properties were as in the wild type, 
with one puzzling exception. Mutein Q38 binds at least tenfold 
more weakly to the high-affinity receptor than the wild-type 
Il2, despite the fact that it has unchanged proliferation ac-
tivity. The basic position 38 has been modified before to an 
acidic one (Arg to Glu) without effect on the proliferative 
activity of the denatured protein [16]. How can the peculiar 
behaviour of mutein Q38 be explained? At the moment, we 
cannot formally exclude a selective instability under the con-
ditions of receptor binding, e. g. cold sensitivity. One might 
visualise, however, another possibility that the occupancy of 
the high-affinity receptor is only one of the determinants of 
the dosefresponse curve during the proliferation assay. 
The binding studies under low-affinity conditions indicate 
that an alteration of position 20 (Asp to Asn) does not affect 
binding to the ß subunit (Tac antigen), whereas an alteration 
ofposition 38 (Arg to Gin) reduces affinity for this protein to 
a major extent. lt will be interesting to see whether the binding 
to the !X subunit is inversely influenced by these mutations. At 
the moment it is tempting to speculate that position Arg-38 
represents part of the binding site for low-affinity-binding ß 
subunit, whereas position Asp-20 is involved in the binding 
to the signal-transducing !X subunit. Possibly only the binding 
to the !X subunit determines the proliferative activity of an Il2 
mutein. 
Interestingly, previous studies with sequence-specific anti-
hodies [14] revealed that antiborlies directed against residues 
8-27 inhibited binding of 112 to YT cells (a subunit) only, 
while antiborlies directed against residues 33-54 specifically 
inhibited binding to MT-1 cells (ß subunit). 
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